RxDoctor Payments Data

Ross Hoffman, MD

Pulmonary Disease · Asheville, NCNPI 1174967673

Payments from drug & device makers

$827in general payments, 2019–2025

Across 27 payments — averaging $30.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$204
  • Boehringer Ingelheim$163
  • Novo Nordisk$129
  • FFF Enterprises, Inc.$97
  • Pharming Healthcare, Inc.$56
  • Astellas Pharma US Inc$49
  • plus $129 from 5 others

What the payments were for

  • Food & beverage$68282%
  • Education$14518%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$827 in reported general payments places this provider in the 40th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$96,428
Medicare patients
368
Services billed
937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter334$249,763
EsbrietPirfenidone15$162,897
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr73$32,961
Spiriva HandihalerTiotropium Bromide30$20,424
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$17,357
SymbicortBudesonide/Formoterol Fumarate43$12,259
Breo ElliptaFluticasone/Vilanterol28$11,161
Albuterol Sulfate HfaAlbuterol Sulfate164$4,935
Varenicline Tartrate15$3,379
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,348
Roflumilast31$2,342
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$2,083
Ventolin HfaAlbuterol Sulfate29$1,783
Levalbuterol Tartrate HfaLevalbuterol Tartrate22$1,693
Wixela InhubFluticasone Propion/Salmeterol13$1,498

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$204$293,885435 claims
Boehringer IngelheimStiolto Respimat$163$17,35733 claims
AstraZenecaSymbicort$13$12,25943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 393 pulmonary disease providers in North Carolina.

Other pulmonary disease in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →